Cancer analgesic
Executive Summary
Natl. Institute on Drug Abuse Director Charles Schuster told a meeting of the Natl. Advisory Council on Drug Abuse Sept. 16 that an NIAD grantee, Tony Yaksh, Mayo Clinic, "has shown that an opioid peptide, D-Ala2-DO-Leu5-enkephalin (DADL), binds to the brain's delta opiate receptor to produce analgesia in cancer patients." Schuster said the discovery is "an important step toward the development of a non-addictive pain-killer that could replace morphine".